跳至主要内容
临床试验/NCT04749238
NCT04749238已完成不适用

Safety and Efficacy Assessment of NucleoCapture Selective DNA Adsorber in Humans

Santersus AG1 个研究点 分布在 1 个国家目标入组 10 人开始时间: 2021年1月26日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
Santersus AG
入组人数
10
试验地点
1
主要终点
Serum urea change over time

研究概览

简要总结

This open non-randomized controlled single center study investigates to what extent the removal of circulating Neutrophil Extracellular Traps (NETs) from blood by NucleoCapture device has a positive effect on the treatment of patients with sepsis and sepsis-associated AKI (SA-AKI).

详细描述

The term "sepsis" refers to a clinical syndrome in which a dysregulation of the host's inflammatory reaction to infection leads to a life-threatening of organ dysfunctions. Sepsis and septic shock are major causes of death in intensive care units worldwide. Sepsis remains the most important cause of AKI in the intensive care unit (ICU) with 15%-20% of patients with sepsis-associated AKI (SA-AKI) prescribed RRT . In addition to association with short term mortality, AKI is also linked to the later development of CKD, ESRD, and long-term increased risk of death

NETosis is a unique form of neutrophil cell death that is characterized by the release of neutrophil extracellular traps (NETs) composed of DNA web-like structures decorated with highly cytotoxic protein components. Release of NETs leads to bystander tissue damage (including the kidneys) and drives a fatal course of disease in sepsis patients.

The plasmapheresis is a medical procedure, where pathogenic components are being removed from the blood by adsorbers outside the body in an extracorporeal circulation. For removal of the pathogenic substances the plasma is separated from the blood to pass the adsorber. The purified plasma is merged with the solid blood components thereafter and returned to the patient. The NucleoCapture device provide highly selective removal of neutrophil extracellular traps from human blood during plasmapheresis procedure.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Male or female ≥ 18 and ≤ 75 years of age.
  • Meet the clinical criteria of sepsis according to the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3))
  • Written informed consent

排除标准

  • A terminal state
  • Active bleeding or uncontrolled acute massive bleeding

结局指标

主要结局

Serum urea change over time

时间窗: from [start of treatment] through 28 days after

Change of urea in serum over time for each patient and in average in group

Incidence of acute kidney injury (AKI)

时间窗: from [start of treatment] through 28 days after

Incidence of acute kidney injury (AKI) in accordance with Kidney Disease Improving Global Outcomes (KDIGO) definitions for AKI

Urine output change

时间窗: from [start of treatment] through 28 days after

Change of urine output over time for each patient and in average in group

Severity of acute kidney injury (AKI)

时间窗: from [start of treatment] through 28 days after

Severity of acute kidney injury (AKI) in accordance with KDIGO definitions for AKI

Rate of AKI transition to the more severe stage (for patients with AKI at baseline).

时间窗: from [start of treatment] through 28 days after

Rate of worsening of acute kidney injury (AKI) in accordance with KDIGO AKI classification (Changing stages from 1 to 2, from 2 to 3).

Serum creatinine change over time

时间窗: from [start of treatment] through 28 days after

Change of creatinine in serum over time for each patient and in average in group

次要结局

  • qSOFA scores change(from [start of treatment] through 28 days after)
  • All-cause mortality(from [start of treatment] through 28 days after)
  • SOFA scores change(from [start of treatment] through 28 days after)

研究者

发起方
Santersus AG
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验